Heartland Advisors Inc. Takes $1.67 Million Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Heartland Advisors Inc. purchased a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 155,850 shares of the biotechnology company’s stock, valued at approximately $1,674,000. Heartland Advisors Inc. owned approximately 0.18% of Anavex Life Sciences as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Berkshire Money Management Inc. bought a new stake in shares of Anavex Life Sciences during the fourth quarter valued at approximately $107,000. Prudential Financial Inc. bought a new stake in shares of Anavex Life Sciences during the fourth quarter worth $109,000. Fiduciary Alliance LLC acquired a new position in shares of Anavex Life Sciences during the fourth quarter valued at $119,000. D.A. Davidson & CO. acquired a new stake in Anavex Life Sciences in the fourth quarter worth about $122,000. Finally, Orion Capital Management LLC raised its holdings in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, February 18th. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Stock Down 8.6 %

Shares of NASDAQ:AVXL opened at $8.72 on Friday. The firm has a market cap of $741.76 million, a price-to-earnings ratio of -15.85 and a beta of 0.94. Anavex Life Sciences Corp. has a 12 month low of $3.25 and a 12 month high of $14.44. The company’s fifty day simple moving average is $9.01 and its 200 day simple moving average is $8.28.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Research analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.